| NEOIMMUNETECH-INC |
NEOIMMUNETECH-INC |
92%
|
we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari® |
| ANIP |
ANI Pharmaceuticals, Inc. |
72%
|
these uncertainties. We are dependent on the commercial success of our only product, Endari®. Our ability to become profitable will depend upon the commercial success of Endari®. In addition to the r… |
| ANIP |
ANI Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ANIP graph: Reciprocal relationship from EMMA graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EMMA graph: these uncertainties. We are depende… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, E… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S. by our internal commercial sales team. I… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S. by our internal commercial sales team. I… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from EMMA graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from EMMA graph: Reciprocal relationship from BMYM… |
| CAH |
Cardinal Health, Inc. |
72%
|
in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S. by our internal commercial sales team. I… |
| CAH |
Cardinal Health, Inc. |
72%
|
Reciprocal relationship from CAH graph: Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, E… |
| CVS |
CVS Health Corporation |
72%
|
in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S. by our internal commercial sales team. I… |
| CVS |
CVS Health Corporation |
72%
|
Reciprocal relationship from CVS graph: Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, E… |
| MCK |
McKesson Corporation |
72%
|
in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, Endari® was marketed and sold in the U.S. by our internal commercial sales team. I… |
| MCK |
McKesson Corporation |
72%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from EMMA graph: in, dyspepsia, burning sensation, and hot flash. Commercialization and Distribution United States Until August 2024, E… |
| AGE-RESEARCH-INC |
AGE-RESEARCH-INC |
62%
|
ldings will be dependent on equity or loan financing from its new owner or other financing sources to continue its activities. As of December 31, 2023, we had loaned EJ Holdings a total of $25.8 mill… |
| AJINOMOTO-AMINOSCIENCE-LLC |
AJINOMOTO-AMINOSCIENCE-LLC |
62%
|
addition, we offer price discounts to our customers in advance of Endari® price increases or as an incentive for bulk or advance orders of Endari®. Such discounts may result in specialty distributor … |
| AJINOMOTO-NORTH-AMERICAN-HOLDINGS-INC |
AJINOMOTO-NORTH-AMERICAN-HOLDINGS-INC |
62%
|
search and development activities in late 2023. Depending on the availability of funds, we may resume research and development of our existing product candidates in the future, and we may seek to acq… |
| AMERISOURCEBERGEN-SPECIALTY-GROUP |
AMERISOURCEBERGEN-SPECIALTY-GROUP |
62%
|
niversity hospitals and community-based out-patient locations. The current focus of our sales team is as follows: • educating prescribers and CBOs on the approved use and benefits of Endari®; and • e… |
| EJ-HOLDINGS-INC |
EJ-HOLDINGS-INC |
62%
|
Act and implementing regulations. Noncompliance with any applicable regulatory requirements can result in refusal to approve products for marketing, warning letters, product recalls or seizure of pro… |
| EJ-HOLDINGS-INC-EJ-HOLDINGS |
EJ-HOLDINGS-INC-EJ-HOLDINGS |
62%
|
Act and implementing regulations. Noncompliance with any applicable regulatory requirements can result in refusal to approve products for marketing, warning letters, product recalls or seizure of pro… |
| EMI-HOLDING-INC |
EMI-HOLDING-INC |
62%
|
NOTE 6—SELECTED FINANCIAL STATEMENT LIABILITIES Accounts payable and accrued expenses as of December 31, 2023 and 2022 consisted of the following (in thousands): December 31, 2023 December 31, 2022 A… |
| GLOBAL-BLOOD-THERAPEUTICS-INC |
GLOBAL-BLOOD-THERAPEUTICS-INC |
62%
|
any adjustments that might result from the outcome of these uncertainties. We are dependent on the commercial success of our only approved product, Endari®. Our ability to become profitable will depe… |
| NOVARTIS-INTERNATIONAL-AG |
NOVARTIS-INTERNATIONAL-AG |
62%
|
ldings will be dependent on equity or loan financing from its new owner or other financing sources to continue its activities. As of December 31, 2023, we had loaned EJ Holdings a total of $25.8 mill… |
| NUTRITION-NORTH-AMERICA-INC |
NUTRITION-NORTH-AMERICA-INC |
62%
|
search and development activities in late 2023. Depending on the availability of funds, we may resume research and development of our existing product candidates in the future, and we may seek to acq… |
| PRESTIGE-CAPITAL-FINANCE-LLC |
PRESTIGE-CAPITAL-FINANCE-LLC |
62%
|
s are combined. No right-of-use asset and related lease liability are recorded for leases with an initial term of 12 months or less. Cash and cash equivalents —Cash and cash equivalents include short… |
